KIT-Mutant GIST in the Second-Line: Evaluating TKI Combinations and Emerging Data

This OncLive News Network program brings together two specialists for a discussion of how second-line treatment for KIT-mutant gastrointestinal stromal tumor (GIST) may be changing. The panelists talk through why treatment becomes harder after first-line therapy stops working, and what the biology of resistance means for the way clinicians choose and sequence agents. They review emerging data on a combination approach that adds an investigational agent to the current second-line standard rather than replacing it, discussing what the results showed on efficacy and on tolerability, and how the combination compares with what has been achievable in this setting until now. The conversation then turns to where things stand from a regulatory standpoint, how such a regimen would fit alongside the therapies already in use, the role of mutation testing in guiding decisions, and where the panelists agree and differ on managing patients today.